엔테라 바이오 (ENTX) 주가

엔테라 바이오(ENTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.96 (-2.31%), 시가총액 $0.07B, 52주 최저~최고 $1.00 ~ $3.14.

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial

핵심 지표

• 현재가: $2.96 (-2.31%)
• 시가총액: $0.07B
• 52주 최저~최고: $1.00 ~ $3.14
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

엔테라 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

엔테라 바이오 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 5.40
• 순이익률: 0.00%
• 영업이익률: -274.50%

자주 묻는 질문